Seeking Alpha

Akorn (AKRX -8%) gets pummeled on a Deutsche downgrade to Hold, citing its high valuation, a...

Akorn (AKRX -8%) gets pummeled on a Deutsche downgrade to Hold, citing its high valuation, a lack of exclusivity for a generic version of Abbott's (ABT -0.6%) Prometrium, and a weaker than expected Vancomycin launch. The firm also cuts its price target to $14 from $15.
From other sites
Comments (1)
  • aldenmac
    , contributor
    Comments (2) | Send Message
     
    The key to AKRX is the transition from being solely a domestic generic drug manufacture to their acquisition of Kilitch ( India). The acquisition of Kilitch was a strategic move. Increase capacity, new markets at the expense of lower gross margin but volume. AKRX must make another acquisition to justify it's multiple to carry it thru the lull before the Killitch acquisition numbers kick( Back half of 2013) in.
    23 Jul 2012, 06:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs